Page 115 - Cardiac Nursing

qxd
96.
9-0
pta
1 A
0
g
P
M
p06
1 A
e 9
03_
LWB K34 0-c 03_ p06 9-0 96. qxd 0 9/0 9/2 009 0 0 8:4 1 A M P a a g e 9 1 A pta ra
K34
0-c
LWB
LWBK340-c03_p069-096.qxd 09/09/2009 08:41 AM Page 91 Aptara
009
8:4
ra
9/0
9/2
C HAPTER 3 / Regulation of Cardiac Output and Blood Pressure 91
54. Jose, P. A., Eisner, G. M., & Felder, R. A. (2003). Dopamine and the 78. Crandall, C. G., Cui, J., & Wilson, T. E. (2003). Effects of heat stress
kidney: A role in hypertension? Current Opinion on Nephrology Hyper- on baroreflex function in humans. Acta Physiologica Scandinavica, 177,
7
7
tension, 12, 189–194. 321–328.
55. Zeng, C., Eisner, G. M., Felder, R. A., et al. (2005). Dopamine receptor 79. Vanhoutte, P., & Leusen, I. (1981). Vasodilatation. New York: Raven
and hypertension. Current Medical and Chemical Cardiovascular Hema- Press.
tology Agents, 3, 69–77. 80. Palmer, T. (2008). Agents acting at the neuromuscular junction and auto-
56. Kellum, J., & Decker, J. (2001). Use of dopamine in acute renal failure: nomic ganglia. In L. L. Brunton & J. S. Lazo (Eds.), Goodman & Gilman’s
A meta-analysis. Critical Care Medicine, 29, 1526–1531. the pharmacological basis of therapeutics. New York: McGraw Hill.
57. Marik, P. E. (2002). Low-dose dopamine: A systematic review. Intensive 81. Myslivecek, J., & Trojan, S. (2003). Regulation of adrenoceptors and
Care Medicine, 28, 877–883. muscarinic receptors in the heart. General Physiology and Biophysics, 22,
58. Friedrich, J. O., Adhikari, N., Herridge, M. S., et al. (2005). Meta- 3–14.
analysis: Low-dose dopamine increases urine output but does not pre- 82. Brodde, O. E., & Michel, M. C. (1999). Adrenergic and muscarinic re-
vent renal dysfunction or death. Annals of Internal Medicine, 142, ceptors in the human heart. Pharmacology in Review, 51, 651–690.
510–524. 83. Brodde, O. E., Bruck, H., Leineweber, K., et al. (2001). Presence, distri-
59. Feigl, E. O. (1998). Neural control of coronary blood flow. Journal of bution and physiological function of adrenergic and muscarinic receptor
6
6
Vascular Research, 35, 85–92. subtypes in the human heart. Basic Research in Cardiology, 96, 528–538.
60. Gauthier, C., Seze-Goismier, C., & Rozec, B. (2007). Beta 3-adreno- 84. Myslivecek, J., Novakova, M., & Klein, M. (2008). Receptor subtype
ceptors in the cardiovascular system. Clinical Hemorheology and Micro- abundance as a tool for effective intracellular signalling. Cardiovascular
7
7
circulation, 37, 193–204. & Hematological Disorders Drug Targets, 8, 66–79.
61. Gauthier, C., Leblais, V., Kobzik, L., et al. (1998). The negative in- 85. Burnstock, G. (2004). Cotransmission. Current Opinion in Pharmacol-
otropic effect of B3-Adrenoreceptor stimulation is mediated by activa- ogy, 4, 47–52.
tion of nitric oxide synthase pathway in human ventricle. Journal of 86. Burnstock, G. (2007). Physiology and pathophysiology of purinergic
Clinical Investigations, 102, 1377–1384. neurotransmission. Physiology in Review, 87, 659–797.
7
7
62. Moniotte, S., Kobzik, L., Feron, O., et al. (2001). Upregulation of 87. Burnstock, G. (2008). Non-synaptic transmission at autonomic neu-
beta(3)-adrenoreceptors and altered contractile response to inotropic roeffector junctions. Neurochemistry International, 52, 14–25.
amines in human failing myocardium. Circulation, 103, 1649–1655. 88. Tsuru, H., Tanimitsu, N., & Hirai, T. (2002). Role of perivascular sympa-
63. Bristow, M., Monobe, W., Pasmussen, R., et al. (1988). Alpha-1 adren- thetic nerves and regional differences in the features of sympathetic inner-
ergic receptors in the nonfailing and failing human heart. Journal of vation of the vascular system. Japanese Journal of Pharmacology, 88, 9–13.
Pharmacology and Experimental Therapeutics, 247, 1039–1045. 89. Burnstock, G. (1996). Purines and cotransmitters in adrenergic and
7
7
64. Franchini, K., & Cowley, A. J. (1996). Autonomic control of cardiac cholinergic neurones. Progress in Brain Research, 68, 193–203.
function. In D. Robertson, P. Low, & R. Polinsky (Eds.), Primer on the 90. Herring, N., Lokale, M. N., Danson, E. J., et al. (2008). Neuropeptide
autonomic nervous system (pp. 42–48). San Diego: Academic Press. Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-
65. Rudner, X. L., Berkowitz, D. E., Booth, J. V., et al. (1999). Subtype spe- mediated, protein kinase C-dependent pathway. Journal of Molecular
4
4
cific regulation of human vascular alpha(1)-adrenergic receptors by ves- and Cellular Cardiology, 44, 477–485.
sel bed and age. Circulation, 100, 2336–2343. 91. Herring, N., & Paterson, D. J. (2009). Neuromodulators of peripheral
66. Borbujo, J., Garcia-Villalon, A., Valle, J., et al. (1989). Postjunctional cardiac sympatho-vagal balance. Experimental Physiology, 94(1), 46–53.
alpha-1 and alpha-2 adrenoreceptors in human skin arteries. An in vitro Epub 2008 Oct 22.
study. Journal of Pharmacology and Experimental Therapeutics, 249, 92. Han, S., Yang, C. L., Chen, X., et al. (1998). Direct evidence for the role
284–287. of neuropeptide Y in sympathetic nerve stimulation-induced vasocon-
4
67. Johnson, J., & Proppe, D. (1996). Cardiovascular adjustments to heat striction. American Journal of Physiology, 274, H290–H294.
4
stress. In M. Fregly & C. Blatteis (Eds.), Handbook of physiology: Section 93. Westfall, T. C., McCullough, L. A., Vickery, L., et al. (1998). Effects of
4. Environmental physiology (pp. 215–243). New York: Oxford Univer- neuropeptide Y at sympathetic neuroeffector junctions. Advances in
sity Press. Pharmacology, 42, 106–110.
68. Charkoudian, N. (2003). Skin blood flow in adult human thermoregu- 94. Abe, K., Tilan, J. U., & Zukowska, Z. (2007). NPY and NPY receptors
7
7
lation: How it works, when it does not, and why. Mayo Clinics Proceed- in vascular remodeling. Current Topics in Medicinal Chemistry, 7,
ing, 78, 603–612. 1704–1709.
69. Kellogg, D. L., Jr. (2006). In vivo mechanisms of cutaneous vasodilation 95. McDermott, B. J., & Bell, D. (2007). NPY and cardiac diseases. Current
and vasoconstriction in humans during thermoregulatory challenges. Topics in Medicinal Chemistry, 7, 1692–1703.
7
7
Journal of Applied Physiology, 100, 1709–1718. 96. Henning, R. J., & Sawmiller, D. R. (2001). Vasoactive intestinal pep-
70. Rowell, L. (1993). Human cardiovascular control. New York: Oxford tide: Cardiovascular effects. Cardiovascular Research, 49, 27–37.
l
l
University Press. 97. Dvorakova, M. C. (2005). Cardioprotective role of the VIP signaling
71. Pergola, P. E., Kellogg, D. L., Jr., Johnson, J. M., et al. (1994). Reflex system. Timely Topics in Medicine, 9, E33.
control of active cutaneous vasodilation by skin temperature in humans. 98. Lundberg, J. M. (1996). Pharmacology of cotransmission in the auto-
American Journal of Physiology, 266, H1979–H1984. nomic nervous system: Integrative aspects on amines, neuropeptides,
6
6
72. Savage, M. V., & Brengelmann, G. L. (1996). Control of skin blood flow adenosine triphosphate, amino acids and nitric oxide. Pharmacology in
in the neutral zone of human body temperature regulation. Journal of Review, 48, 113–178.
Applied Physiology, 80, 1249–1257. 99. Rowell, L. (1996). Human circulation: Regulation during physical stress.
73. Rowell, L., O’Leary, D., & Kellogg, D. (1996). Integration of cardio- New York: Oxford University Press.
vascular control systems in dynamic exercise. In L. Rowell & J. Sheperd 100. Westfall, T. C., & Westfall, D. P. (2008). Adrenergic agonists and antag-
(Eds.), Handbook of physiology, exercise: Regulation and integration of onists. In L. Brunton, K. Parker, N. Murri, et al. (Eds.), Goodman &
multiple systems (pp. 770–838). Bethesda, MD: Oxford University Gilman’s pharmacology. New York: McGraw-Hill.
Press. 101. Barrett, L., Singer, M., & Clapp, L. (2007). Vasopressin: Mechanisms
74. Kellogg, D. L., Jr., Pergola, P. E., Piest, K. L., et al. (1995). Cutaneous of action on the vasculature in health and septic shock. Critical Care
active vasodilation in humans is mediated by cholinergic nerve cotrans- Medicine, 35, 33–40.
7
7
mission. Circulation Research, 77, 1222–1228. 102. Treschan, T., & Peters, J. (2006). The vasopressin system: Physiology
75. Kellogg, D. L., Jr., Zhao, J. L., & Wu, Y. (2008). Endothelial nitric ox- and clinical strategies. Anesthesiology, 105, 599–612.
ide synthase control mechanisms in the cutaneous vasculature of humans 103. Bie, P. (1980). Osmoreceptors, vasopressin, and control of renal water
in vivo. American Journal of Physiology Heart and Circulatory Physiology, excretion. Physiology in Review, 60, 961–1048.
295, H123–H129. 104. Ramsay, D. J., Thrasher, T. N., & Bie, P. (1988). Endocrine components
76. Kellogg, D. L., Jr., Zhao, J. L., & Wu, Y. (2008). Neuronal nitric oxide of body fluid homeostasis. Comparative Biochemistry and Physiology, 90,
synthase control mechanisms in the cutaneous vasculature of humans in 777–780.
6
6
vivo. Journal of Physiology, 586, 847–857. 105. Voisin, D. L., & Bourque, C. W. (2002). Integration of sodium and os-
77. Joyner, M. J., & Dietz, N. M. (2003). Sympathetic vasodilation in hu- mosensory signals in vasopressin neurons. Trends in Neuroscience, 25,
7
7
man muscle. Acta Physiologica Scandinavica, 177, 329–336. 199–205.